Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Syndecan-1/CD138 Antibody (B-A38), Novus Biologicals™

Mouse Monoclonal Antibody has been used in 16 publications
Supplier: Novus Biologicals NB10064980100UG
Description
Syndecan-1/CD138 Monoclonal specifically detects Syndecan-1/CD138 in Human samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
Syndecan-1/CD138 | |
Monoclonal | |
0.10 mg/mL | |
Western Blot 1:100-1:2000, Flow Cytometry Neat, Immunohistochemistry 1:10-1:500, Immunocytochemistry/Immunofluorescence 1:10-1:500, Immunohistochemistry-Paraffin 1:100-1:500, Immunohistochemistry-Frozen 1:100-1:500 | |
P18827 | |
SDC1 | |
U266 cell line | |
Primary | |
NB100-64980 recognizes a heparan sulfate rich membrane glycoprotein of 200kD known as Syndecan-1 (CD138). Syndecan functions as a receptor for collagen, fibronectin and thrombospondin. NB100-64980 stains all plasma cells and plasma cell lines. No staining of other leucocytes is seen in peripheral blood or bone marrow, although some ALL cell lines express the antigen weakly. Some staining of epithelial and endothelial cells may be seen in immunohistology. | |
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
B-A38 | |
Unconjugated | |
Phosphate buffered saline with 0.09% sodium azide | |
CD138, CD138 antigen, SDC, SYND1heparan sulfate proteoglycan fibroblast growth factor receptor, syndecan, syndecan 1, syndecan proteoglycan 1, syndecan-1 | |
Mouse | |
100 μg | |
6382 | |
Human | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction